ATE305933T1 - Piperazin derivate - Google Patents

Piperazin derivate

Info

Publication number: ATE305933T1
Authority: AT; Austria
Prior art keywords: piperazine derivatives; piperazine; derivatives
Prior art date: 2000-07-31

Application number

AT01962869T

Other languages

English (en)

Inventor

Jonathan Mark Bentley

Paul Hebeisen

Marc Muller

Hans Richter

Stephan Roever

Patrizio Mattei

Sven Taylor

Original Assignee

Hoffmann La Roche

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-31

Filing date

2001-07-24

Publication date

2005-10-15

2001-07-24 Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305933T1 publication Critical patent/ATE305933T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01962869T 2000-07-31 2001-07-24 Piperazin derivate ATE305933T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00116517		2000-07-31
PCT/EP2001/008520 WO2002010169A1 (en)	2000-07-31	2001-07-24	Piperazine derivatives

Publications (1)

Publication Number	Publication Date
ATE305933T1 true ATE305933T1 (de)	2005-10-15

Family

ID=8169405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01962869T ATE305933T1 (de)	2000-07-31	2001-07-24	Piperazin derivate

Country Status (20)

Country	Link
US (4)	US20020035110A1 (de)
EP (1)	EP1325008B1 (de)
JP (1)	JP4180365B2 (de)
KR (1)	KR100539139B1 (de)
CN (1)	CN1277828C (de)
AR (1)	AR030306A1 (de)
AT (1)	ATE305933T1 (de)
AU (2)	AU8395501A (de)
BR (1)	BR0112918A (de)
CA (1)	CA2417106C (de)
DE (1)	DE60113865T2 (de)
DK (1)	DK1325008T3 (de)
ES (1)	ES2250459T3 (de)
GT (1)	GT200100155A (de)
MX (1)	MXPA03000906A (de)
PA (1)	PA8523601A1 (de)
PE (1)	PE20020366A1 (de)
UY (1)	UY26863A1 (de)
WO (1)	WO2002010169A1 (de)
ZA (1)	ZA200300525B (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE305933T1 (de) *	2000-07-31	2005-10-15	Hoffmann La Roche	Piperazin derivate
GB0106177D0 (en)	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
AU2003220886A1 (en)	2002-03-29	2003-10-13	Mitsubishi Pharma Corporation	Remedy for sleep disturbance
NZ536664A (en)	2002-06-19	2007-07-27	Biovitrum Ab	Piperazinylpyrazine derivative compounds, their use and preparation
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
DE10319612A1 (de) *	2003-05-02	2004-11-18	Bayer Healthcare Ag	Substituierte Dihydrochinazoline
DE10320780A1 (de) *	2003-05-09	2005-01-20	Bayer Healthcare Ag	Heterocyclyl-substituierte Dihydrochinazoline
GB0314967D0 (en) *	2003-06-26	2003-07-30	Hoffmann La Roche	Piperazine derivatives
US20050032930A1 (en) *	2003-07-02	2005-02-10	Christian Jackson	Inkjet ink
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
DE10352499A1 (de) *	2003-11-11	2005-06-09	Bayer Healthcare Ag	Substituierte Dihydrochinazoline II
EP2305352A1 (de)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen
DE102004022672A1 (de) *	2004-05-07	2005-11-24	Bayer Healthcare Ag	Substituierte Azachinazoline
EP2400300A1 (de)	2004-08-25	2011-12-28	Takeda Pharmaceutical Company Limited	Screeningverfahren von Mitteln zur Prävention/Behandlung von stressbedingter Harninkontinenz
CA2584806C (en)	2004-11-01	2014-06-17	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
EP2322616A1 (de)	2004-11-12	2011-05-18	Asuragen, Inc.	Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
US7790712B2 (en)	2005-03-17	2010-09-07	Boehringer Ingelheim Pharmaceutical, Inc.	Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
AU2006243243B2 (en) *	2005-05-03	2009-05-14	F. Hoffmann-La Roche Ag	Tetracyclic azapyrazinoindolines as 5-HT2 ligands
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
JP5154927B2 (ja)	2005-05-30	2013-02-27	Ｍｓｄ株式会社	新規ピペリジン誘導体
DE102005027517A1 (de) *	2005-06-15	2006-12-21	Bayer Healthcare Ag	Verfahren zur Herstellung von Dihydrochinazolinen
WO2007018248A1 (ja)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	ピリドン化合物
EP2330124B1 (de)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Hybridpolypeptide mit auswählbaren Eigenschaften
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
US7875633B2 (en)	2005-08-24	2011-01-25	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (de)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
AU2006308635A1 (en) *	2005-10-14	2007-05-10	H. Lundbeck A/S	Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (de)	2005-10-27	2012-01-04	Msd Kk	Neue benzoxathiinderivate
AU2006312557B2 (en)	2005-11-10	2011-12-08	Msd K.K.	Aza-substituted spiro derivative
KR20080085014A (ko)	2005-12-09	2008-09-22	에프. 호프만-라 로슈 아게	비만 치료에 유용한 트라이사이클릭 아마이드 유도체
UA95788C2 (en)	2005-12-15	2011-09-12	Ф. Хоффманн-Ля Рош Аг	Fused pyrrole derivatives
EP2742936A1 (de)	2006-05-16	2014-06-18	Takeda Pharmaceutical Company Limited	Kondensierte heterocyclische Verbindung und ihre Verwendung
CA2664113C (en)	2006-09-22	2013-05-28	Merck & Co., Inc.	Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (fr)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Dérivé diarylcétimine
JP5271918B2 (ja)	2007-01-16	2013-08-21	アイピントゥル，エルエルシー	メタボリック症候群治療用の新規組成物
FR2912145B1 (fr) *	2007-02-02	2009-03-06	Servier Lab	Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008120653A1 (ja)	2007-04-02	2008-10-09	Banyu Pharmaceutical Co., Ltd.	インドールジオン誘導体
MY162157A (en)	2007-04-16	2017-05-31	Abbott Lab	Substituted indole mcl-1 inhibitors
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
US20100266504A1 (en)	2007-11-15	2010-10-21	Takahiro Matsumoto	Condensed pyridine derivative and use thereof
EP2264026A4 (de)	2008-03-06	2012-03-28	Msd Kk	Alkylaminopyridinderivate
EP2254886B1 (de) *	2008-03-28	2016-05-25	Nerviano Medical Sciences S.r.l.	3,4-dihydro-2h-pyrazino[1,2-a]indol-1-on derivate als kinase inhibitoren, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen
AU2009229860A1 (en)	2008-03-28	2009-10-01	Msd K.K.	Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2722653A1 (en) *	2008-04-28	2009-11-05	Kuraray Medical Inc.	Dental composition and composite resin
CA2666036C (en)	2008-05-16	2017-09-12	Chien-Hung Chen	Novel compositions and methods for treating hyperproliferative diseases
AU2009256157B2 (en)	2008-06-04	2014-12-18	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diaryl ketoxime derivative technical field
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CA2741125A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (es)	2008-10-30	2011-11-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida
CN102271509A (zh)	2008-10-31	2011-12-07	默沙东公司	用于抗糖尿病药的新型环苯并咪唑衍生物
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (de)	2008-12-16	2011-10-26	Schering Corporation	Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
FI122466B (fi) *	2009-08-21	2012-01-31	Hollming Oy	Menetelmä työstettävän metallikappaleen kuumentamiseksi ja induktiokuumennustyökalu
US20120253036A1 (en)	2009-12-11	2012-10-04	Yukinori Nagakura	Agent for treating fibromyalgia
WO2011106273A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
KR101668514B1 (ko)	2011-02-25	2016-10-21	머크 샤프 앤드 돔 코포레이션	항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
CN108676076A (zh)	2011-03-01	2018-10-19	辛纳吉制药公司	制备鸟苷酸环化酶c激动剂的方法
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
ME02660B (de)	2012-03-16	2017-06-20	Vitae Pharmaceuticals Inc	Leber-x-rezeptormodulatoren
LT2825541T (lt)	2012-03-16	2016-12-27	Vitae Pharmaceuticals, Inc.	Kepenų x receptoriaus moduliatoriai
TWI579274B (zh) *	2012-04-20	2017-04-21	龍馬躍公司	製備１－芳基－５－烷基吡唑化合物的改良方法
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP2970119B1 (de)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Neuartige indolderivate als antidiabetika
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
WO2014173903A1 (en) *	2013-04-23	2014-10-30	Laboratorios Del Dr. Esteve, S.A.	PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
ES2754385T3 (es) *	2013-04-23	2020-04-17	Esteve Pharmaceuticals Sa	Compuestos de pirazino-[1,2-a]indol, su preparación y uso en medicamentos
EP4424697A2 (de)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultrareine agonisten der guanylatcyclase c, verfahren zur herstellung und verwendung davon
SI3097107T1 (sl)	2014-01-24	2019-08-30	Turning Point Therapeutics, Inc.	Diarilni makrocikli kot modulatorji protein kinaz
CA2959208C (en)	2014-08-29	2023-09-19	Tes Pharma S.R.L.	Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
PL3766885T3 (pl)	2015-06-17	2022-09-19	Pfizer Inc.	Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
CN107735399B (zh)	2015-07-02	2021-01-26	特普医药公司	作为蛋白质激酶的调节剂的手性二芳基大环
CN109952292A (zh)	2016-10-14	2019-06-28	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3733204A4 (de)	2017-12-27	2021-09-15	Takeda Pharmaceutical Company Limited	Therapeutikum für belastungsinkontinenz und stuhlinkontinenz
BR112021009589A2 (pt)	2018-11-20	2021-08-17	Tes Pharma S.R.L.	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (de)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
AU2021329805B2 (en)	2020-08-18	2024-02-29	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US652018A (en) *	1900-02-15	1900-06-19	John C Duner	Gate.
US3317524A (en)	1965-02-04	1967-05-02	American Home Prod	Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
DE2162422A1 (de)	1971-12-16	1973-06-20	Merck Patent Gmbh	Pyrazinoindol-derivate und verfahren zu ihrer herstellung
EP0572863A1 (de) *	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
US5622950A (en) *	1993-03-01	1997-04-22	Merck, Sharp & Dohme Ltd.	Pyrrolo-pyridine derivatives
HUT71799A (en)	1993-03-01	1996-02-28	Merck Sharp & Dohme	Pyrrolo-pyridine derivatives, pharmaceutical compositions containing the same, process for producing them
US5576319A (en) *	1993-03-01	1996-11-19	Merck, Sharp & Dohme Ltd.	Pyrrolo-pyridine derivatives
US6169086B1 (en)	1997-01-27	2001-01-02	Daiichi Pharmaceutical Co., Ltd.	Pyrazole derivatives
JP2000169475A (ja)	1998-07-24	2000-06-20	Dai Ichi Seiyaku Co Ltd	ピラゾ―ル誘導体およびその塩
CZ20012193A3 (cs) *	1998-12-17	2001-12-12	American Home Products Corporation	Deriváty 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a)chinoxalin-5(6H)onu, způsob jejich výroby a jejich pouľití
GB9902047D0 (en) *	1999-01-29	1999-03-17	Cerebrus Ltd	Chemical compounds XI
ATE305933T1 (de) *	2000-07-31	2005-10-15	Hoffmann La Roche	Piperazin derivate

2001
- 2001-07-24 AT AT01962869T patent/ATE305933T1/de not_active IP Right Cessation
- 2001-07-24 CN CNB018152260A patent/CN1277828C/zh not_active Expired - Fee Related
- 2001-07-24 BR BR0112918-0A patent/BR0112918A/pt not_active IP Right Cessation
- 2001-07-24 JP JP2002515898A patent/JP4180365B2/ja not_active Expired - Fee Related
- 2001-07-24 ES ES01962869T patent/ES2250459T3/es not_active Expired - Lifetime
- 2001-07-24 WO PCT/EP2001/008520 patent/WO2002010169A1/en active IP Right Grant
- 2001-07-24 KR KR10-2003-7001439A patent/KR100539139B1/ko not_active IP Right Cessation
- 2001-07-24 DK DK01962869T patent/DK1325008T3/da active
- 2001-07-24 AU AU8395501A patent/AU8395501A/xx active Pending
- 2001-07-24 CA CA002417106A patent/CA2417106C/en not_active Expired - Fee Related
- 2001-07-24 DE DE60113865T patent/DE60113865T2/de not_active Expired - Fee Related
- 2001-07-24 MX MXPA03000906A patent/MXPA03000906A/es active IP Right Grant
- 2001-07-24 EP EP01962869A patent/EP1325008B1/de not_active Expired - Lifetime
- 2001-07-24 AU AU2001283955A patent/AU2001283955B2/en not_active Ceased
- 2001-07-25 US US09/912,949 patent/US20020035110A1/en not_active Abandoned
- 2001-07-25 PE PE2001000749A patent/PE20020366A1/es not_active Application Discontinuation
- 2001-07-27 AR ARP010103589A patent/AR030306A1/es unknown
- 2001-07-30 UY UY26863A patent/UY26863A1/es not_active Application Discontinuation
- 2001-07-30 PA PA20018523601A patent/PA8523601A1/es unknown
- 2001-07-30 GT GT200100155A patent/GT200100155A/es unknown
2003
- 2003-01-20 ZA ZA200300525A patent/ZA200300525B/en unknown
- 2003-03-25 US US10/396,242 patent/US6933387B2/en not_active Expired - Fee Related
2005
- 2005-06-28 US US11/169,079 patent/US7253281B2/en not_active Expired - Fee Related
2007
- 2007-01-03 US US11/649,132 patent/US20070106076A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60113865T2 (de)	2006-07-20
EP1325008B1 (de)	2005-10-05
US6933387B2 (en)	2005-08-23
KR100539139B1 (ko)	2005-12-26
JP2004505085A (ja)	2004-02-19
AU2001283955B2 (en)	2006-05-18
UY26863A1 (es)	2002-01-31
DE60113865D1 (de)	2006-02-16
PA8523601A1 (es)	2002-10-24
ES2250459T3 (es)	2006-04-16
US20030216401A1 (en)	2003-11-20
CA2417106A1 (en)	2002-02-07
DK1325008T3 (da)	2006-02-13
CA2417106C (en)	2007-09-18
CN1452622A (zh)	2003-10-29
US20070106076A1 (en)	2007-05-10
CN1277828C (zh)	2006-10-04
KR20030020954A (ko)	2003-03-10
ZA200300525B (en)	2004-04-20
PE20020366A1 (es)	2002-05-17
US20020035110A1 (en)	2002-03-21
AR030306A1 (es)	2003-08-20
EP1325008A1 (de)	2003-07-09
MXPA03000906A (es)	2005-02-24
WO2002010169A1 (en)	2002-02-07
BR0112918A (pt)	2003-07-01
US20050239789A1 (en)	2005-10-27
JP4180365B2 (ja)	2008-11-12
US7253281B2 (en)	2007-08-07
GT200100155A (es)	2002-05-16
AU8395501A (en)	2002-02-13

Legal Events

Date

Code

Title

Description

2006-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1325008

Country of ref document: EP

2011-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE305933T1 (de)	2005-10-15	Piperazin derivate
DE60134338D1 (de)	2008-07-17	Piperazin-derivate
IS6546A (is)	2002-09-10	Nýjar píperazín afleiður
DE60120366D1 (de)	2006-07-20	Arylkondensiete azapolycyclische derivate
DE60009147D1 (de)	2004-04-22	Admantan derivate
CH1175401H1 (de)	2007-02-15	Piperazin Derivate verwendbar als CCR5 Antagonisten
DK1198453T5 (da)	2005-01-31	N-(indolcarbonyl-)piperazinderivater
NO20043079L (no)	2004-09-21	Piperazinderivat
NO20023787L (no)	2002-10-11	Piperazin- og piperidinderivater
ATE273980T1 (de)	2004-09-15	6-phenylpyrrolopyrimidindion derivate
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DE60013127D1 (de)	2004-09-23	5-phenyl-pyrimidine derivate
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
DE69930543D1 (de)	2006-05-11	Piperazin-derivate
NO20031572L (no)	2003-06-10	Brodannete piperazinderivater
ATE294787T1 (de)	2005-05-15	Piperazin derivate mit sst1 antagonistischer wirkung
ATE317389T1 (de)	2006-02-15	4-phenyl-pyrimidine derivate
DE60129174D1 (de)	2007-08-09	Neue pleuromutilin derivate
NO20023954L (no)	2002-09-30	Substituerte piperasinforbindelser
ATE280752T1 (de)	2004-11-15	Aminomethyl-phenyl-cyclohexanonderivate
ATE496034T1 (de)	2011-02-15	Phtalazinon derivate
DE60103859D1 (de)	2004-07-22	2-phenylpyran-4-on derivate
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate